Drugs / LFA102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01610050 | Jun 2012 → Feb 2014 | breast carcinoma, castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01338831 | Sep 2011 → Mar 2014 | breast cancer, leiomyoma, male reproductive organ cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LFA102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01610050 ↗ |
| Action | Inhibit | “binds to and inhibits the PRLR” PMID 27091421 ↗ Apr 2016 |
| Modality | Monoclonal antibody | “LFA102, a humanized monoclonal antibody (mAb) that binds to and inhibits the PRLR, has exhibited promising preclinical antitumor activity.” PMID 27091421 ↗ Apr 2016 |
| Route | Intravenous | “received doses of LFA102 at 3-60 mg/kg intravenously once every 4 weeks.” PMID 27091421 ↗ Apr 2016 |
| Target | PRLR | “binds to and inhibits the PRLR” PMID 27091421 ↗ Apr 2016 |